Results 41 to 50 of about 2,936,789 (384)

Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

Nature Reviews Cardiology, 2022
Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability.
Diana A Gorog, R. Storey, P. Gurbel, U. Tantry, J. Berger, M. Chan, D. Duerschmied, S. Smyth, William A. E. Parker, R. Ajjan, G. Vilahur, L. Badimón, J. Berg, H. Cate, F. Peyvandi, Taia T. Wang, R. Becker   +16 more
semanticscholar   +1 more source

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program [PDF]

, 2017
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's ...
Albin, Roger, Alcalay, Roy N., Babcock, Debra, Bowman, F. DuBois, Chen-Plotkin, Alice, David, Karen K., Dawson, Ted M., Dewey, Richard B., Jr., Foroud, Tatiana, German, Dwight, Gwinn, Katrina, Huang, Xuemei, Lungu, Codrin, Petyuk, Vlad, Potashkin, Judith A., Rosenthal, Liana S., Saunders-Pullman, Rachel, Scherzer, Clemens R., Sieber, Beth-Anne, St Hillaire-Clarke, Coryse, Sutherland, Margaret, Swanson-Fischer, Christine, Vaillancourt, David E., Walt, David R., West, Andrew B., Zhang, Jing   +25 more
core   +1 more source

A combined clinical and biomarker approach to predict diuretic response in acute heart failure [PDF]

, 2015
Background: Poor diuretic response in acute heart failure is related to poor clinical outcome. The underlying mechanisms and pathophysiology behind diuretic resistance are incompletely understood.
Bloomfield, Daniel M., Bruno, Noemi, Cleland, John G.F., Cotter, Gad, Damman, Kevin, Davison, Beth, Dittrich, Howard C., Givertz, Michael M., Hillege, Hans L., Metra, Marco, O’Connor, Christopher M., Ponikowski, Piotr, Teerlink, John R., ter Maaten, Jozine M., Valente, Mattia A.E., van Veldhuisen, Dirk J., Voors, Adriaan A.   +16 more
core   +4 more sources

Biomarkers for Stroke [PDF]

Journal of Stroke, 2013
Major stroke clinical trials have failed during the past decades. The failures suggest the presence of heterogeneity among stroke patients. Biomarkers refer to indicators found in the blood, other body fluids or tissues that predicts physiologic or disease states, increased disease risk, or pharmacologic responses to a therapeutic intervention.
Suk Jae Kim, Gyeong Joon Moon, Oh Young Bang   +2 more
openaire   +3 more sources

The Tumor Cytosol miRNAs, Fluid miRNAs, and Exosome miRNAs in Lung Cancer. [PDF]

, 2014
The focus of this review is to provide an update on the progress of microRNAs (miRNAs) as potential biomarkers for lung cancer. miRNAs are single-stranded, small non-coding RNAs that regulate gene expression and show tissue-specific signatures ...
Haisheng eXu, Wenbin eDeng, Wenbin eDeng, Wenrong eGong, Xin eQin   +4 more
core   +2 more sources

ST2 and Multimarker Testing in Acute Decompensated Heart Failure [PDF]

, 2015
Most data on heart failure biomarkers have been derived from patient cohorts with chronic disease. However, risk prediction in patients admitted with acute decompensated heart failure (ADHF) remains a challenge.
Antoni, Md, Bayes, Genis, DI SOMMA, Salvatore, Maisel, Alan S., Md,, Md,, Md,, Mebazaa, Alexandre   +7 more
core   +1 more source

Biomarker Jeopardy

Journal of the Advanced Practitioner in Oncology, 2022
In the popular Biomarker Jeopardy session, Sandra E. Kurtin, PhD, ANP-C, AOCN®, Alyssa Henglefelt, PharmD, BCOP, and Haleigh Mistry, MS, PA-C, paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and discussed guidelines for biomarker ...
Kurtin, Sandra E., Henglefelt, Alyssa, Mistry, Haleigh   +2 more
openaire   +2 more sources

Characterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury

Biomarker Insights, 2012
After traumatic brain injury (TBI), glial fibrillary acidic protein (GFAP) and other brain-derived proteins and their breakdown products are released into biofluids such as CSF and blood.
J. Susie Zoltewicz, Dancia Scharf, Boxuan Yang, Aarti Chawla, Kimberly J. Newsom, Lijuan Fang   +5 more
doaj   +1 more source

Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases

Molecular Metabolism, 2021
Background: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and ...
Nina Sonne, Morten A. Karsdal, Kim Henriksen   +2 more
doaj   +1 more source

Definition of valid proteomic biomarkers: a bayesian solution [PDF]

, 2009
Clinical proteomics is suffering from high hopes generated by reports on apparent biomarkers, most of which could not be later substantiated via validation.
C.C. Holmes, E. Check, E.F. Petricoin, H. Mischak, J. Albert, J. Jantos-Siwy, J.J. Coon, K. Bae, R.M. Everson, S. Decramer, S. Manocha   +10 more
core   +1 more source